Research location
San Mateo
California, United States
Advertisement
Research activity in San Mateo
California, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 172 trials and 176 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in San Mateo
172 linked trials · page 1 of 4Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialNCT07391774 · 2026-08-10 · 1 site observation
RECRUITING
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)NCT06616584 · 2025-05-22 · 1 site observation
RECRUITING
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerNCT06790693 · 2025-04-09 · 1 site observation
RECRUITING
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)NCT06116682 · 2024-11-19 · 1 site observation
RECRUITING
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceNCT06492616 · 2024-09-27 · 1 site observation
RECRUITING
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)NCT06031688 · 2024-08-08 · 1 site observation
RECRUITING
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerNCT06058377 · 2023-11-27 · 1 site observation
RECRUITING
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25NCT05879926 · 2023-10-18 · 1 site observation
RECRUITING
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerNCT05929768 · 2023-09-15 · 1 site observation
RECRUITING
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerNCT05624996 · 2023-07-12 · 1 site observation
RECRUITING
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabNCT05812807 · 2023-06-14 · 1 site observation
RECRUITING
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)NCT05642572 · 2023-05-05 · 1 site observation
RECRUITING
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])NCT04267848 · 2020-06-16 · 1 site observation
RECRUITING
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerNCT03851445 · 2019-02-06 · 1 site observation
RECRUITING
The PREDICT Registry:NCT03448926 · 2018-02-27 · 1 site observation
RECRUITING
Argus 2.0 Adoption StudyNCT07425236 · 2026-04-19 · 1 site observation
NOT_YET_RECRUITING
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With DiabetesNCT07228117 · 2026-02-02 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 DiabetesNCT07076199 · 2025-08-11 · 1 site observation
ACTIVE_NOT_RECRUITING
SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients With Type 1 and Type 2 DiabetesNCT06719531 · 2025-05-01 · 1 site observation
WITHDRAWN
Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialNCT06671912 · 2025-02-19 · 1 site observation
SUSPENDED
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk AsthmaNCT06676319 · 2024-11-07 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).NCT06551324 · 2024-10-21 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With AsthmaNCT06261957 · 2024-05-31 · 1 site observation
COMPLETED
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06221969 · 2024-01-16 · 1 site observation
COMPLETED
A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 9)NCT05823948 · 2023-04-11 · 1 site observation
COMPLETED
A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and OverweightNCT05486065 · 2022-08-08 · 1 site observation
COMPLETED
Evidence for Health Improvement in People With Diabetes Using One Touch & Partner SolutionsNCT05354297 · 2022-07-26 · 1 site observation
UNKNOWN
Evaluation of a Digital Diabetes Self-Management Education and Support ProgramNCT05368454 · 2022-05-31 · 1 site observation
COMPLETED
In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 DiabetesNCT05238142 · 2022-02-25 · 1 site observation
COMPLETED
Symptomatic Relief of Action Tremor With Cala Trio Using Trio+ BandsNCT05480215 · 2021-10-07 · 1 site observation
COMPLETED
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close MonitoringNCT04597359 · 2021-10-05 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)NCT04848480 · 2021-04-30 · 1 site observation
COMPLETED
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)NCT04625647 · 2021-04-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 DiabetesNCT04419779 · 2021-03-08 · 1 site observation
SUSPENDED
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialNCT04457596 · 2021-03-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal TherapyNCT04379570 · 2021-02-15 · 1 site observation
ACTIVE_NOT_RECRUITING
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialNCT04513717 · 2021-01-21 · 1 site observation
ACTIVE_NOT_RECRUITING
A Digital Flu Intervention for People With Cardiovascular ConditionsNCT04584645 · 2020-09-21 · 1 site observation
COMPLETED
Gan & Lee Evaluation of New Biosimilar for Type 1 LisproNCT04254380 · 2019-12-04 · 1 site observation
WITHDRAWN
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 DiabetesNCT04090242 · 2019-09-06 · 1 site observation
TERMINATED
Diabetes Autoimmunity Withdrawn In New Onset and In Established PatientsNCT03895437 · 2019-06-17 · 1 site observation
TERMINATED
Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin DegludecNCT03938740 · 2019-03-18 · 1 site observation
COMPLETED
Comparative User Experiences With BD Nano™ PRO 32G Extra Thin Wall Pen Needle vs the Terumo Nanopass® 34G Pen NeedleNCT03878745 · 2019-02-11 · 1 site observation
COMPLETED
Mylan Insulin Aspart StudyNCT03760068 · 2018-11-07 · 1 site observation
COMPLETED
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid TumorsNCT03375320 · 2018-10-26 · 1 site observation
ACTIVE_NOT_RECRUITING
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or ObesityNCT03574597 · 2018-10-24 · 1 site observation
COMPLETED
Influenza Vaccination Digital Interventions for People Living With DiabetesNCT03870997 · 2018-09-12 · 1 site observation
COMPLETED
Use of CoG by Patients With Diabetes MellitusNCT03840161 · 2018-07-16 · 1 site observation
COMPLETED
Diabetes Coaching Program for Medicare Advantage Members With Type 2 Diabetes - Impact on A1cNCT03363100 · 2017-12-05 · 1 site observation
COMPLETED
Continuous Monitoring and Control of HypoglycemiaNCT03340831 · 2017-10-20 · 1 site observation
UNKNOWN
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.